Association of estrogen receptor alpha (ERα) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors

Gynecological Endocrinology

Volumn 28, Issue 11, 2012, Pages 859-862

  Koukouras, Dimitrios ^a   Marioli, Dimitra J ^a   Papadopoulos, Kostas ^a   Adonakis, George L ^a   Armeni, Anastasia K ^a   Georgopoulos, Neoklis A ^a   Decavalas, George ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Aromatase inhibitors; Breast cancer; Endometrial thickness; Estrogen receptor alpha (ER ) gene polymorphisms

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENDOMETRIUM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84867508407     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.671393     Document Type: Article

References (23)

1. Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, et al. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 2004;64:8891-8900.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55: 10-30.
3. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285.
4. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-282.
5. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-670.
6. Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W. Genetic polymorphisms in the estrogen receptor α gene and risk of breast cancer: Results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2003;12:853-859.
7. Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, et al. Oestrogen receptor α gene haplotype and postmenopausal breast cancer risk: A case control study. Breast Cancer Res 2004;6:R437-R449.
8. Georgopoulos NA, Adonakis GL, Fotopoulos A, Koika V, Spinos N, Saltamavros A, Keramopoulos A, et al. Estrogen receptor polymorphisms in tamoxifen-treated women with breast cancer. Gynecol Endocrinol 2006;22:185-189.
9. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442.
10. Vogel VG. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Curr Drug Targets 2011;12:1874-1887.
11. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
12. Monnier A. Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol 2007;18 Suppl 8:viii36-viii44.
13. Breast International Group (BIG) 1-98 Collaborative Group, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
14. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: An overview. Oncologist 2006;11:553-562.
15. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Clack G, Bianco AR; ATAC Trialists' Group The ATAC adjuvant breast-cancer trial: Six year results of the endometrial sub protocol. J Obstet Gynecol 2010;30:596-604.
16. Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I, Lolis D. Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril 1999;72:164-166.
17. Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, et al. Oestrogen receptor-α gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod 2001;16:51-55.
18. Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clin Interv Aging 2008;3:647-657.
19. Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 2005;93:61-66.
20. Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P. Aromatase inhibitors for breast cancer: Different structures, same effects? Endocr Relat Cancer 2008;15:27-36.
21. Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004;10:5717-5723.
22. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Clack G, Bianco AR; ATAC Trialists' Group. The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol. J Obstet Gynaecol 2010;30:596-604.
23. Gonelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clinical Interventions in Aging 2008;3:647-657.